Hormone blockade no advantage over surveillance

MEDPAGE TODAY – Mar. 17, 2014 – A data analysis of more than 15,000 men diagnosed with prostate cancer showed that the 3,435 men whose first or primary treatment was hormone blockade lived no longer compared to men who chose watchful waiting, or monitoring. The results overturn a widely held assumption that blocking male hormones would provide an advantage to men who did not want to undergo surgery or radiation but wanted to do something more than surveillance. The study results are in the Journal of Clinical Oncology.

Read more …